66 related articles for article (PubMed ID: 16985323)
21. Cathepsin B in the growth of colorectal cancer: increased activity of cathepsin B in human colorectal cancer.
Satoh Y; Higashi T; Nouso K; Shiota T; Kinugasa N; Yoshida K; Uematsu S; Nakatsukasa H; Nishimura Y; Tsuji T
Acta Med Okayama; 1996 Dec; 50(6):305-11. PubMed ID: 8985467
[TBL] [Abstract][Full Text] [Related]
22. [Nuclear morphometric analysis of colorectal adenocarcinoma and its clinicopathologic significance].
Yi PY; Yang GH; Tan YS
Zhonghua Bing Li Xue Za Zhi; 1994; 23(3):141-3. PubMed ID: 7954951
[TBL] [Abstract][Full Text] [Related]
23. Cathepsin-D and tumor associated antigen DF3 in salivary gland neoplasia. Differential diagnostic and prognostic applications.
Vigneswaran N; Müller S; DeRose P; Cohen C
Pathol Res Pract; 1994 Dec; 190(12):1174-84. PubMed ID: 7540754
[TBL] [Abstract][Full Text] [Related]
24. [Expression of cathepsin B and its clinical importance in colorectal cancer].
Yu B; Li SY; An P; Zuo FY; Cai HY
Zhonghua Wei Chang Wai Ke Za Zhi; 2005 Nov; 8(6):507-9. PubMed ID: 16299652
[TBL] [Abstract][Full Text] [Related]
25. Quantitative analysis of survivin in colorectal adenocarcinoma: increased expression and correlation with telomerase activity.
Lam AK; Saleh S; Smith RA; Ho YH
Hum Pathol; 2008 Aug; 39(8):1229-33. PubMed ID: 18547619
[TBL] [Abstract][Full Text] [Related]
26. Small Bowel Adenocarcinoma Frequently Exhibits Lynch Syndrome-associated Mismatch Repair Protein Deficiency But Does Not Harbor Sporadic MLH1 Deficiency.
Xia M; Singhi AD; Dudley B; Brand R; Nikiforova M; Pai RK
Appl Immunohistochem Mol Morphol; 2017 Jul; 25(6):399-406. PubMed ID: 27258561
[TBL] [Abstract][Full Text] [Related]
27. Medullary-type poorly differentiated adenocarcinoma of the large bowel: a distinct clinicopathologic entity characterized by microsatellite instability and improved survival.
Lanza G; Gafà R; Matteuzzi M; Santini A
J Clin Oncol; 1999 Aug; 17(8):2429-38. PubMed ID: 10561306
[TBL] [Abstract][Full Text] [Related]
28. Cathepsin D as a potential prognostic marker for lung adenocarcinoma.
Mimae T; Tsuta K; Maeshima AM; Okada M; Asamura H; Kondo T; Tsuda H
Pathol Res Pract; 2012 Sep; 208(9):534-40. PubMed ID: 22824147
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical molecular markers as predictors of curability of endoscopically resected submucosal colorectal cancer.
Kaneko I; Tanaka S; Oka S; Yoshida S; Hiyama T; Arihiro K; Shimamoto F; Chayama K
World J Gastroenterol; 2007 Jul; 13(28):3829-35. PubMed ID: 17657837
[TBL] [Abstract][Full Text] [Related]
30. GAEC1 and colorectal cancer: a study of the relationships between a novel oncogene and clinicopathologic features.
Gopalan V; Smith RA; Nassiri MR; Yasuda K; Salajegheh A; Kim SY; Ho YH; Weinstein S; Tang JC; Lam AK
Hum Pathol; 2010 Jul; 41(7):1009-15. PubMed ID: 20236690
[TBL] [Abstract][Full Text] [Related]
31. Activity of cathepsin B and D in colorectal cancer: relationships with tumour budding.
Guzińska-Ustymowicz K; Zalewski B; Kasacka I; Piotrowski Z; Skrzydlewska E
Anticancer Res; 2004; 24(5A):2847-51. PubMed ID: 15517887
[TBL] [Abstract][Full Text] [Related]
32. The immunohistochemical expression of cathepsin D in colorectal cancer.
Valentini AM; Pirrelli M; Armentano R; Caruso ML
Anticancer Res; 1996; 16(1):77-80. PubMed ID: 8615673
[TBL] [Abstract][Full Text] [Related]
33. Clinical prognostic factors and expression of cathepsin D in endometrioid adenocarcinoma.
Dvalishvili I; Charkviani L; Charkviani T; Turashvili G; Burkadze G
Georgian Med News; 2005 Sep; (126):27-31. PubMed ID: 16234588
[TBL] [Abstract][Full Text] [Related]
34. Expression of CDX-2 and Ki-67 in different grades of colorectal adenocarcinomas.
Sen A; Mitra S; Das RN; Dasgupta S; Saha K; Chatterjee U; Mukherjee K; Datta C; Chattopadhyay BK
Indian J Pathol Microbiol; 2015; 58(2):158-62. PubMed ID: 25885126
[TBL] [Abstract][Full Text] [Related]
35. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.
Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT
Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622
[TBL] [Abstract][Full Text] [Related]
36. Expressions of chromogranin A and cathepsin D in human primary hepatocellular carcinoma.
Huang XF; Wang CM; Dai XW; Li ZJ; Pan BR; Yu LB; Qian B; Fang L
World J Gastroenterol; 2000 Oct; 6(5):693-698. PubMed ID: 11819676
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathologic and molecular profiles of microsatellite unstable Barrett Esophagus-associated adenocarcinoma.
Farris AB; Demicco EG; Le LP; Finberg KE; Miller J; Mandal R; Fukuoka J; Cohen C; Gaissert HA; Zukerberg LR; Lauwers GY; Iafrate AJ; Mino-Kenudson M
Am J Surg Pathol; 2011 May; 35(5):647-55. PubMed ID: 21422910
[TBL] [Abstract][Full Text] [Related]
38. LEF-1 is frequently expressed in colorectal carcinoma and not in other gastrointestinal tract adenocarcinomas: an immunohistochemical survey of 602 gastrointestinal tract neoplasms.
Kermanshahi TR; Jayachandran P; Chang DT; Pai R
Appl Immunohistochem Mol Morphol; 2014; 22(10):728-34. PubMed ID: 25394300
[TBL] [Abstract][Full Text] [Related]
39. Up-regulation of PTEN at the transcriptional level is an adverse prognostic factor in female lung adenocarcinomas.
Inamura K; Togashi Y; Nomura K; Ninomiya H; Hiramatsu M; Okui M; Satoh Y; Okumura S; Nakagawa K; Tsuchiya E; Ishikawa Y
Lung Cancer; 2007 Aug; 57(2):201-6. PubMed ID: 17452061
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical expression of cathepsin D in laryngeal epithelial lesions: correlation with CD44 expression, p53 and Rb status and proliferation associated indices.
Goussia A; Ioachim E; Peschos D; Assimakopoulos D; Vougiouklakis T; Skevas A; Agnantis N
Anticancer Res; 1999; 19(4B):3055-60. PubMed ID: 10652592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
